Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Akerna Corp is a health information services business based in the US. Akerna shares (KERN) are listed on the NASDAQ and all prices are listed in US Dollars. Akerna employs 204 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.15 |
|---|---|
| 52-week range | $0.13 - $4.04 |
| 50-day moving average | $0.47 |
| 200-day moving average | $1.57 |
| Wall St. target price | $3.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.67 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.151 from 2022-07-01
| 1 week (2022-06-28) | -50.49% |
|---|---|
| 1 month (2022-06-01) | -63.24% |
| 3 months (2022-04-05) | -85.48% |
| 6 months (2022-01-05) | -91.12% |
| 1 year (2021-07-02) | -96.28% |
|---|---|
| 2 years (2020-07-02) | -98.16% |
| 3 years (2019-07-05) | 14.32 |
| 5 years (2017-07-01) | N/A |
| Revenue TTM | $23.6 million |
|---|---|
| Gross profit TTM | $12.6 million |
| Return on assets TTM | -15.31% |
| Return on equity TTM | -93.14% |
| Profit margin | -198.22% |
| Book value | $1.13 |
| Market capitalisation | $4.8 million |
TTM: trailing 12 months
We're not expecting Akerna to pay a dividend over the next 12 months.
Over the last 12 months, Akerna's shares have ranged in value from as little as $0.13 up to $4.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akerna's is 2.9044. This would suggest that Akerna's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that offers tracking, reporting, and compliance tools to cannabis cultivators, processors, sellers, and clinics. Further, it provides cannabis cultivation management and compliance software; and cannabis tracking technology that offers seed-to-sale-to-self data. Akerna Corp.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.